Don’t just focus on one activity – doing a variety every week gives you more health benefits, a study suggests.
Category Archives: Mind Building
Finally explained: Why kidney disease is so deadly for the heart

Scientists have uncovered a key reason why more than half of people with chronic kidney disease eventually die from heart-related complications. According to new research, damaged kidneys release a substance into the bloodstream that directly harms the heart.
The discovery, made by researchers at UVA Health and Mount Sinai, could help doctors spot high-risk patients earlier and open the door to new treatments aimed at preventing or slowing heart failure in people with kidney disease.
“Kidney and heart disease can develop silently, so they are often discovered only after damage has already been done,” said researcher Uta Erdbrügger, MD, an internal medicine physician-scientist with the University of Virginia School of Medicine’s Division of Nephrology. “Our findings can help to identify patients at risk for heart failure earlier, enabling earlier treatment and improved outcomes.”
Heart Failure Risk in Chronic Kidney Disease
Chronic kidney disease affects more than 1 in 7 Americans, or roughly 35 million people in the United States, according to the National Institutes of Health. The condition is especially common among people with other health issues. About 1 in 3 patients with diabetes and around 1 in 5 people with hypertension (high blood pressure) also have kidney disease.
Doctors have long known that chronic kidney disease and cardiovascular disease are closely connected, with more severe kidney damage linked to worse heart outcomes. However, understanding exactly why this happens has been difficult. Many patients share overlapping risk factors such as obesity and high blood pressure, making it hard to determine whether the kidneys themselves play a direct role in harming the heart.
A Kidney-Specific Cause Identified
Until now, researchers had not been able to identify a kidney-specific factor that directly damages the heart. The new study led by Erdbrügger and her colleagues points to a clear culprit. Diseased kidneys release tiny particles known as “circulating extracellular vesicles” into the bloodstream.
Extracellular vesicles are produced by nearly all cells and normally act as messengers, transporting proteins and other materials between cells. In people with chronic kidney disease, however, these vesicles carry small, non-coding RNA called miRNA that the researchers found to be toxic to heart tissue.
Lab and Patient Evidence
In laboratory mice, preventing these extracellular vesicles from circulating led to noticeable improvements in heart function and reduced signs of heart failure. The research team also analyzed blood plasma samples from people with chronic kidney disease and from healthy individuals. Harmful extracellular vesicles were found in patients with kidney disease but not in healthy volunteers.
“Doctors always wondered how organs such as the kidney and heart communicate with each other. We show that EVs from the kidney can travel to the heart and be toxic,” Erdbrügger said. “We are just at the beginning to understand this communication.”
Toward Earlier Detection and New Treatments
The findings suggest that a blood test could one day be developed to identify people with chronic kidney disease who face the highest risk of serious heart problems. Researchers may also be able to design therapies that block or neutralize these circulating extracellular vesicles, reducing their damaging effects on the heart.
“Our hope is to develop novel biomarkers and treatment options for our kidney patients at risk for heart disease,” Erdbrügger said. “Potentially our work will improve precision medicine for CKD and Heart failure patients, so that each patient gets the exact treatment they need.”
Advancing Extracellular Vesicle Research
To help move this field forward, Erdbrügger is organizing a hands-on workshop for UVA scientists focused specifically on extracellular vesicle research. The five-day workshop begins Feb. 7.
Finding answers to the most pressing medical mysteries and developing new treatments for complex diseases are key goals of UVA’s new Paul and Diane Manning Institute of Biotechnology. The institute is designed to speed the transition from laboratory discoveries to real-world therapies that can save lives.
Findings Published
The research findings were published in the scientific journal Circulation. The article is open access, meaning it is available to read for free.
The research team included Xisheng Li Nikhil Raisinghani, Alex Gallinat, Carlos G. Santos-Gallego, Shihong Zhang, Sabrina La Salvia, Seonghun Yoon, Hayrettin Yavuz, Anh Phan, Alan Shao, Michael Harding, David Sachs, Carol Levy, Navneet Dogra, Rupangi Vasavada, Nicole Dubois, Erdbrügger and Susmita Sahoo. The scientists reported no financial conflicts of interest.
The study was funded by the National Institute of Health through grants HL140469, HL124187, HL148786, R01DK125856, 1-INO-2025-1704-A-N, R21AG07848, and R01DK133598.
Scientists identify hidden protein interaction driving Parkinson’s disease

About 1 million people in the United States are living with Parkinson’s disease, and nearly 90,000 new cases are diagnosed each year, according to the Parkinson’s Foundation. The condition is a long-term, progressive brain disorder that gradually destroys dopamine-producing nerve cells, which are critical for controlled, fluid movement.
Most available treatments focus on easing symptoms, but their benefits often fade over time. Now, researchers at Case Western Reserve University have identified a specific biological pathway that contributes to the underlying damage caused by the disease.
A Harmful Protein Chain Reaction
The study, recently published in Molecular Neurodegeneration, explains how the buildup of toxic proteins inside brain cells leads to the death of neurons responsible for movement, a hallmark of Parkinson’s disease.
“We’ve uncovered a harmful interaction between proteins that damages the brain’s cellular powerhouses, called mitochondria,” said Xin Qi, the study’s senior author and Jeanette M. and Joseph S. Silber Professor of Brain Sciences at the Case Western Reserve School of Medicine. “More importantly, we’ve developed a targeted approach that can block this interaction and restore healthy brain cell function.”
After three years of investigation, the team discovered that alpha-synuclein, a protein known to accumulate in Parkinson’s disease, abnormally binds to an enzyme called ClpP. This enzyme normally helps maintain cellular health, but the interaction disrupts its function.
Damage to the Brain’s Energy Supply
When alpha-synuclein interferes with ClpP, mitochondria begin to fail. These structures act as the cell’s energy generators, and their impairment triggers widespread neurodegeneration and brain cell loss. Experiments across several research models also showed that this molecular interaction speeds up the progression of Parkinson’s disease.
To counter this process, the researchers developed a treatment known as CS2. The compound is designed to block the damaging protein interaction and help mitochondria recover their normal function. CS2 acts as a decoy, drawing alpha-synuclein away from ClpP and preventing it from harming the cell’s energy systems.
In multiple study models, including human brain tissue, patient-derived neurons and mice models, CS2 reduced brain inflammation and led to improvements in movement and cognitive performance.
Targeting the Disease, Not Just Symptoms
“This represents a fundamentally new approach to treating Parkinson’s disease,” said Di Hu, a research scientist in the School of Medicine’s Department of Physiology and Biophysics. “Instead of just treating the symptoms, we’re targeting one of the root causes of the disease itself.”
The breakthrough builds on Case Western Reserve’s strengths in mitochondrial biology and neurodegenerative disease research, along with its collaborative environment and advanced experimental models. These resources helped translate basic biological insights into a potential therapeutic strategy.
Next Steps Toward Clinical Use
Over the next five years, the team aims to move the discovery closer to human clinical trials. Planned efforts include refining the drug for use in people, expanding safety and effectiveness testing, identifying key molecular biomarkers tied to disease progression, and advancing toward patient-focused treatments.
“One day,” Qi said, “we hope to develop mitochondria-targeted therapies that will enable people to regain normal function and quality of life, transforming Parkinson’s from a crippling, progressive condition into a manageable or resolved one.”
Doctor accused of sex assaults on 38 patients
The charges relate to alleged offences against patients, including children, in the West Midlands.
Scientists solve a major roadblock holding back cancer cell therapy

For the first time, researchers at the University of British Columbia have shown how to consistently produce a crucial type of human immune cell, known as helper T cells, from stem cells in a controlled lab setting.
The research, published on January 7 in Cell Stem Cell, removes a major barrier that has slowed the development, affordability, and large-scale production of cell therapies. By solving this problem, the work could help make off-the-shelf treatments more accessible and effective for conditions such as cancer, infectious diseases, autoimmune disorders, and more.
“Engineered cell therapies are transforming modern medicine,” said co-senior author Dr. Peter Zandstra, professor and director of the UBC School of Biomedical Engineering. “This study addresses one of the biggest challenges in making these lifesaving treatments accessible to more people, showing for the first time a reliable and scalable way to grow multiple immune cell types.”
The Promise and Limits of Living Drugs
Over the past several years, engineered cell therapies such as CAR-T treatments have produced dramatic, sometimes lifesaving results for people with cancers that were once considered untreatable. These therapies work by reprogramming a patient’s immune cells to recognize and destroy disease, effectively turning those cells into ‘living drugs’.
Even with their success, cell therapies remain costly, complex to manufacture, and out of reach for many patients around the world. One key reason is that most existing treatments rely on a patient’s own immune cells, which must be collected and specially prepared over several weeks for each individual.
“The long-term goal is to have off-the-shelf cell therapies that are manufactured ahead of time and on a larger scale from a renewable source like stem cells,” said co-senior author Dr. Megan Levings, a professor of surgery and biomedical engineering at UBC. “This would make treatments much more cost-effective and ready when patients need them.”
Cancer cell therapies are most effective when two types of immune cells work together. Killer T cells directly attack infected or cancerous cells. Helper T cells, which act as the immune system’s conductors — detecting health threats, activating other immune cells and sustaining the immune responses over time — play a central coordinating role.
While scientists have made progress using stem cells to create killer T cells in the lab, they have not been able to reliably generate helper T cells until now.
“Helper T cells are essential for a strong and lasting immune response,” said Dr. Levings. “It’s critical that we have both to maximize the efficacy and flexibility of off-the-shelf therapies.”
A Key Advance Toward Stem Cell Based Immune Therapies
In the new study, the UBC research team addressed this long-standing challenge by carefully adjusting biological signals that guide how stem cells develop. This approach allowed them to precisely control whether stem cells became helper T cells or killer T cells.
The scientists found that a developmental signal known as Notch plays an important but time-sensitive role in immune cell formation. Notch is necessary early in development, but if the signal stays active for too long, it blocks the formation of helper T cells.
“By precisely tuning when and how much this signal is reduced, we were able to direct stem cells to become either helper or killer T cells,” said co-first author Dr. Ross Jones, a research associate in the Zandstra Lab. “We were able to do this in controlled laboratory conditions that are directly applicable in real-world biomanufacturing, which is an essential step toward turning this discovery into a viable therapy.”
The team also confirmed that the lab-grown helper T cells functioned like real immune cells, not just in appearance but in behavior. The cells showed signs of full maturity, carried a wide variety of immune receptors, and were able to develop into specialized subtypes with distinct immune roles.
“These cells look and act like genuine human helper T cells,” said co-first author Kevin Salim, a UBC PhD student in the Levings Lab. “That’s critical for future therapeutic potential.”
Researchers say the ability to generate both helper and killer T cells, and to carefully control their balance, could greatly improve the effectiveness of stem cell-derived immune therapies.
“This is a major step forward in our ability to develop scalable and affordable immune cell therapies,” said Dr. Zandstra. “This technology now forms the foundation for testing the role of helper T cells in supporting the elimination of cancer cells and generating new types of helper T cell-derived cells, such as regulatory T cells, for clinical applications.”
‘Just bad luck’: The teenage cousins living with inoperable brain tumours
Lachlan Lindsay and Hazel Dempster were both diagnosed with brain tumours as children.
The hospitals where waiting times are getting worse. Is yours one of them?
Nearly a quarter of hospital trusts in England have seen waiting times deteriorate in the past year.
A “dormant” brain protein turns out to be a powerful switch

Researchers at Johns Hopkins Medicine report that they have uncovered a promising drug target that could allow scientists to increase or decrease the activity of specific brain proteins. The discovery may lead to new treatments for psychiatric conditions such as anxiety and schizophrenia, as well as a neurological disorder that affects movement and balance. The work was supported by funding from the National Institutes of Health.
The proteins at the center of the research are known as delta-type ionotropic glutamate receptors, or GluDs. These proteins are known to play an important role in how neurons communicate with each other. According to the researchers, mutations in GluDs have been linked to psychiatric disorders, including anxiety and schizophrenia. Despite this connection, scientists have struggled for years to understand exactly how these proteins work, making it difficult to design treatments that could regulate their activity.
“This class of protein has long been thought to be sitting dormant in the brain,” says Edward Twomey, Ph.D., assistant professor of biophysics and biophysical chemistry at the Johns Hopkins University School of Medicine. “Our findings indicate they are very much active and offer a potential channel to develop new therapies.”
The study describing these findings was published in Nature.
Imaging Reveals How GluDs Function
To better understand GluDs, Twomey and his team used cryo-electron microscopy, an advanced imaging technique that allows scientists to visualize proteins in fine detail. Their analysis showed that GluDs contain an ion channel at their center. This channel holds charged particles that help the proteins interact with neurotransmitters (electrical signals that allow brain cells to communicate with one another).
“This process is fundamental for the formation of synapses, the connection point where cells communicate,” says Twomey.
Implications for Movement Disorders and Mental Illness
The discovery could help accelerate the development of drugs for cerebellar ataxia, a disorder that affects movement and balance. Cerebellar ataxia can result from stroke, head injury, brain tumors, or certain neurodegenerative diseases, and it may also cause memory problems. In this condition, GluDs become “super-active” even when there is no electrical signaling in the brain. Twomey explains that a potential treatment approach would involve developing drugs that block this excessive activity.
In schizophrenia, the situation appears to be reversed. GluDs are less active than normal, and Twomey says future drugs could aim to boost their activity instead.
Potential Links to Aging and Memory Loss
The findings may also be relevant to aging and memory decline. Because GluDs help regulate synapses, drugs that target these proteins could help maintain synapse function over time. Synapses are essential for learning, memory, and the formation of thoughts.
“Because GluDs directly regulate synapses, we could potentially develop a targeted drug for any condition where synapses malfunction,” Twomey says.
Next Steps and Ongoing Research
Looking ahead, Twomey says he plans to collaborate with pharmaceutical companies to further develop this therapeutic target. His team is also studying specific GluD mutations that have been directly linked to schizophrenia, anxiety, and other psychiatric disorders. The goal is to better understand how these conditions progress and to design more precise treatments.
Other Johns Hopkins scientists who contributed to the study include Haobo Wang, Fairine Ahmed, Jeffrey Khau, and Anish Kumar Mondal.
The Johns Hopkins University has filed a patent covering the techniques used to measure electrical currents from GluDs.
Funding for the research came from the National Institutes of Health (R35GM154904), the Searle Scholars Program, and the Diana Helis Henry Medical Research Foundation.
Inside the mysterious collapse of dark matter halos

For nearly 100 years, dark matter has remained one of the biggest unanswered questions in cosmology. Although it cannot be seen directly, its gravitational influence shapes galaxies and the large-scale structure of the universe. At the Perimeter Institute, two physicists are investigating how a particular form of dark matter, known as self-interacting dark matter (SIDM), may influence the way cosmic structures grow and change over time.
In research published in Physical Review Letters, James Gurian and Simon May introduce a new computational tool designed to study how SIDM affects galaxy formation. Their approach makes it possible to explore types of particle interactions that were previously difficult or impractical to model accurately.
When Dark Matter Interacts With Itself
SIDM is a theoretical form of dark matter whose particles can collide with one another but do not interact with baryonic matter, the familiar matter made of protons, neutrons, and electrons. These collisions conserve energy through what physicists call elastic self-interactions. This behavior can strongly influence dark matter halos, the massive concentrations of dark matter that surround galaxies and help guide their evolution.
“Dark matter forms relatively diffuse clumps which are still much denser than the average density of the universe,” says Gurian, a Perimeter postdoctoral fellow and co-author of the study. “The Milky Way and other galaxies live in these dark matter halos.”
Heat, Energy Flow, and Core Collapse
The self-interacting nature of SIDM can trigger a process known as gravothermal collapse within dark matter halos. This phenomenon arises from a counterintuitive property of gravity, where systems bound by gravity become hotter as they lose energy rather than cooling down.
“You have this self-interacting dark matter which transports energy, and it tends to transport energy outwards in these halos,” says Gurian. “This leads to the inner core getting really hot and dense as energy is transported outwards.” Over time, this process can drive the core of the halo toward a dramatic collapse.
A Missing Link in Dark Matter Modeling
Simulating the structures formed by SIDM has long been a challenge. Existing methods work well only under certain conditions. Some simulations perform best when dark matter is sparse and collisions are rare, while others are effective only when dark matter is extremely dense and interactions are frequent.
“One approach is an N-body simulation approach that works really well when dark matter is not very dense and collisions are infrequent. The other approach is a fluid approach — and this works when dark matter is very dense and collisions are frequent.”
“But for the in-between, there wasn’t a good method,” Gurian says. “You need an intermediate range approach to correctly go between the low-density and high-density parts. That was the origin of this project.”
A Faster and More Accessible Simulation Tool
To solve this problem, Gurian and his co-author Simon May, a former Perimeter postdoctoral researcher now serving as an ERC Preparative Fellow at Bielefeld University, developed a new code called KISS-SIDM. The software bridges the gap between existing simulation methods, delivering higher accuracy while requiring far less computing power. It is also publicly available for other researchers.
“Before, if you wanted to check different parameters for self-interacting dark matter, you needed to either use this really simplified fluid model, or go to a cluster, which is computationally expensive. This code is faster, and you can run it on your laptop,” says Gurian.
Opening the Door to New Dark Matter Physics
Interest in interacting dark matter has grown in recent years, partly due to puzzling features seen in galaxies that may not fit standard models.
“There has been considerable interest recently in interacting dark matter models, due to possible anomalies detected in observations of galaxies that may require new physics in the dark sector,” says Neal Dalal, a member of the Perimeter Institute research faculty.
“Previously, it was not possible to perform accurate calculations of cosmic structure formation in these sorts of models, but the method developed by James and Simon provides a solution that finally allows us to simulate the evolution of dark matter in models with significant interactions,” Dalal says. “Their paper should enable a broad spectrum of studies that previously were intractable.”
Implications for Black Holes and Beyond
The collapse of dark matter cores is especially intriguing because it may leave observable signatures, including possible connections to black hole formation. However, how this process ultimately ends remains an open question.
“The fundamental question is, what’s the final endpoint of this collapse? That’s what we’d really like to do — study the phase after you form a black hole.”
By making it possible to explore these extreme conditions in detail, the new code represents an important step toward answering some of the deepest questions about dark matter and the structure of the universe.
This tiny power module could change how the world uses energy

Global demand for electricity is rising fast. Energy-hungry data centers that support artificial intelligence, along with expanding manufacturing, are putting unprecedented pressure on power systems worldwide. Meeting that demand will require more than simply generating additional electricity.
One promising solution is to use existing energy supplies far more efficiently and at lower cost.
A New Approach to Power Efficiency
Researchers at the National Renewable Energy Laboratory (NREL) have developed a new silicon carbide based power module designed to dramatically improve how electricity is converted and delivered. A power module is the housing that contains power electronics, which regulate the flow of electricity between systems. This new design delivers record-breaking efficiency, higher power density, and a manufacturing process that keeps costs low.
The technology is known as NREL’s Ultra-Low Inductance Smart power module, or ULIS. By using silicon carbide semiconductors, ULIS can achieve five times the energy density of earlier designs while taking up less space. That combination allows manufacturers to build equipment that is smaller, lighter, and more energy efficient. The 1200-volt, 400-amp module is well suited for data centers, electrical grids, microreactors, and heavy-duty platforms such as next-generation aircraft and military vehicles.
Why Ultra-Low Inductance Matters
A key advantage of ULIS is its exceptionally low parasitic inductance, which refers to resistance that slows changes in electrical current and limits efficient power conversion. ULIS reduces this resistance by seven to nine times compared with today’s most advanced silicon carbide power modules.
Because the system can switch electrical current extremely quickly and efficiently, it converts more of the available electricity into usable power. That capability allows ULIS to extract significantly more value from the same energy supply, making it a strong candidate for addressing growing global energy needs.
“We consider ULIS to be a true breakthrough,” said Faisal Khan, NREL’s chief power electronics researcher and the principal investigator for the project. “It’s a future-proofed, ultrafast power module that will make the next generation of power converters more affordable, efficient, and compact.”
Built for Reliability in Extreme Conditions
ULIS is designed not only for efficiency, but also for reliability in demanding environments. According to Khan, the lightweight yet powerful module can monitor its own condition and anticipate component failures before they happen.
This feature is especially critical for high-risk applications such as aviation and military operations. For aircraft operating at 30,000 feet or vehicles navigating combat zones, early failure detection can be the difference between mission success and catastrophic loss.
“ULIS was a truly organic effort, built entirely in-house here at NREL,” Khan said. “We are very excited to demonstrate its strengths in real-world settings.”
A Radical Redesign for Lower Cost Manufacturing
Many of ULIS’ performance gains come from a completely new physical design.
Traditional power modules stack semiconductor devices inside box-like packages. ULIS instead arranges its circuitry in a flat, octagonal layout. This disk-shaped structure fits more components into a smaller footprint, reducing both size and weight. At the same time, its innovative current routing minimizes magnetic interference, which helps deliver cleaner electrical output and higher overall efficiency.
“Our biggest concern was that the device switches off and on very quickly, and we needed a layout that wouldn’t create a chokepoint within the design,” said Shuofeng Zhao, an NREL power electronics researcher who designed ULIS’ flux cancellation architecture.
Early concepts explored complex three-dimensional shapes, including designs resembling flowers or hollow cylinders. However, these ideas proved too expensive or difficult to manufacture. The breakthrough came when the team simplified the concept into a nearly two-dimensional structure. Sarwar Islam, another NREL power electronics researcher, proposed the flattened design that balanced performance, cost, and manufacturability.
“We squished it flat, like a pancake,” Zhao said, “and suddenly we had a low-cost, high-performing design that was much easier to fabricate.”
Joshua Major, also part of the NREL power electronics team, developed new fabrication methods that allowed the intricate structure to be produced using only in-house tools and facilities. The result was a design that combined the electrical advantages of three-dimensional systems with the practicality of flat manufacturing.
Flexible Materials and Wireless Control
ULIS also departs from conventional materials. Traditional power modules bond copper directly to rigid ceramic bases to conduct electricity and manage heat. While effective, this approach limits flexibility.
Instead, ULIS bonds copper to a flexible polymer called Temprion. This change produces a thinner, lighter, and more adaptable structure. The material bonds to copper using only heat and pressure, and its components can be machined with widely available equipment. As a result, manufacturing costs fall into the hundreds of dollars rather than the thousands.
Another major advance allows ULIS to operate wirelessly. The module can be controlled and monitored without physical cables, functioning as a self-contained unit. This modular, Lego-like design allows it to be integrated into a wide range of systems, from data center servers to advanced aircraft and military vehicles. A patent for the low-latency wireless communication protocol, led by Sarwar Islam, is currently pending.
Designed for Future Technologies
While ULIS currently relies on advanced silicon carbide semiconductors, the design was intentionally built to evolve. The module can be adapted for future semiconductor materials, including gallium nitride and gallium oxide, which has not yet reached commercial use.
Together, these innovations support a central goal. As societies become increasingly dependent on reliable electricity, ULIS is designed to deliver efficiency without sacrificing dependability.
Where ULIS Could Make the Biggest Difference
ULIS is expected to have broad impact across multiple sectors.
In the U.S. power grid, electricity must be converted into usable forms before it reaches consumers. This process often depends on large, low-frequency equipment that wastes energy. ULIS’ fast switching improves efficiency while its ability to tolerate high temperatures may reduce long-term maintenance costs.
In aviation, the module’s ability to move electricity quickly and conserve energy enables lighter and more powerful converters. This could help make electric vertical takeoff and landing (eVTOL) aircraft more practical and commercially viable.
ULIS could also play a role in future fusion energy systems. Although commercial fusion remains under development, these systems will require compact and reliable pulsed power components. ULIS’ ultralow inductance and durable design make it well suited for that challenge.
As industries pursue more reliable electricity, advanced artificial intelligence, and next-generation vehicles, ULIS is now available for licensing.
